Home > A. Molecular pathology > Targeted therapy > Small molecules > dabrafenib

dabrafenib

Tuesday 24 June 2014

Tafinlar

WKP

Dabrafenib (trade name Tafinlar) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF .

Dabrafenib acts as an inhibitor of the associated enzyme B-Raf (BRAF ), which plays a role in the regulation of cell growth.

Therapy

- Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.

- 72% ORR to dabrafenib in paediatric patients with BRAF V600E-mutated low-grade glioma in BRAF V600-mutated population., setting the scene for BRAFi / MEKi combinations